Personalizing
Cancer Treatment for Everyone

WEBINAR

Panel of Doctors Answer Your Questions About Cancer

Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar. 

Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio. 

Cancer Treatment Doctor
Bringing state-of-the-art precision cancer care Bringing state-of-the-art precision cancer care to rural communities

Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT. 

Dr. Belisario Arango covered the following topics:

Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients? 
Where is the future of cancer care going?

VIEW ALL ARTICLES

PRESS RELEASES

alleywatch selin kurnaz
Women in NYC Tech: Selin Kurnaz of Massive Bio Are you a woman in NYC Tech and interested in participating in this series? Make sure to read the whole article…

By Alleywatch

September 19, 2017

Much has been said and written about the lack of women in the tech sector, be it as investors (or associates), founders, or in management positions at major companies. Is the problem the old boys network – or that success in technology is seen as a young man’s game? In this series, we speak with some of the top women in tech in New York as they discuss the challenges they face, the perceptions that need to be changed and the work that’s being done – or not – to help to promote women in tech.

Today we speak with Dr. Selin Kurnaz, CEO and cofounder of Massive Bio. After emigrating from Turkey and completing a PhD at the University of Michigan, receiving multiple engineering degrees, Selin spent more than a specializing in delivering revenue enhancement, margin optimization and capital efficiency improvements for Pharmaceutical and Life Science companies. Her startup, Massive Bio, brings the latest knowledge in cancer care to patients treated at community practices in the US and worldwide. Selin has written and spoke extensively about life sciences in tech and how to deliver information in creative ways.

Massive Bio in Health IT meeting
Massive Bio was part of first AI & big data health tech program in New York launched by INTO

Into Global Business Communications Co., Ltd. (INTO) organized the first AI & big data health tech program successfully in New York this April.

Dr. Belisario and Kim Thiboldeaux
Massive Bio Team Meets with the Cancer Moonshot Project and the Biden Cancer Initiative in Washington, D.C.

On June 27, 2017,  a member of the Massive Bio Team, Belisario A. Arango, M.D., took part of the Cancer Moonshot Project and the Biden Cancer Initiative Meeting in Washington, D.C.  The meeting was hosted by Kim Thiboldeaux, CEO of Cancer Support Community and a member of the Board of Directors of the Biden Cancer  Initiative. The purpose of this meeting was to update the cancer community on the accomplishments over the past year, since the announcement of the Moonshot challenge, and to discuss the goals that are expected to be reached over the next 4 years.

Massive Bio in Latin America
Massive Bio expands its oncology advisory services to Latin America

For Latin America, headquartered in Colombia, home of regional nascent IT and startup boom, Massive Bio will now broadcast in Caracol International which reaches to 14+ million subscribers.

VIEW ALL ARTICLES

IN THE NEWS

In this file photo from 2013, Stephanie Lipscomb was getting ready to undergo a 20 minute MRI scan at the Duke Cancer Center after undergoing a pioneering treatment using injections of the polio virus into her brain to shrink a tumor. Now four years later
Duke researchers say they have a breakthrough in treating brain cancer

Duke University cancer researchers said Wednesday they have produced compelling research that shows a patient’s own immune system can be used to attack brain cancer cells.

Scientists found that a molecule called mIR-124 plays an important role in determining whether or not a particular type of cancer cell responds to chemotherapeutic agents.
Single molecule determines lung cancer cell death
Researchers have identified a molecule that determines whether or not a type of lung cancer cell will undergo cancer cell death. This discovery may lead to better approaches to lung cancer treatment, specialists say.
A simple test which can detect gene mutations in tumor DNA from blood samples is giving new choices to lung cancer patients with faster diagnosis and improved access to life changing drugs.
Simple blood test provides new treatment choices to lung cancer patients

University Hospitals Birmingham NHS Foundation Trust and Roche Diagnostics introduce pioneering approach to lung cancer diagnosis

Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers
FDA approves first biosimilar for the treatment of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

VIEW ALL ARTICLES

PUBLISHED RESEARCH

Researchers Tackle Ovarian Cancer Using a Multidisciplinary Approach
Researchers Tackle Ovarian Cancer Using a Multidisciplinary Approach

September is National Ovarian Cancer Awareness Month. Ovarian cancer is among the most deadly of all cancers, though because of less awareness, most cities won’t be as blanketed in teal (ovarian cancer’s awareness color) as they are bathed in pink for October’s focus on breast cancer. But researchers at the Harper Cancer Research Institute, which is a collaboration between the University of Notre Dame and the Indiana University School of Medicine South Bend (IUSM-SB), are working with community partners to not only foster awareness of ovarian cancer, but to develop tests for early detection, create novel chemotherapies, and target the Holy Grail: A cure.

The effect of health insurance on childhood cancer survival has not been well studied.
The effect of health insurance on childhood cancer survival in the United States

The effect of health insurance on childhood cancer survival has not been well studied. Using Surveillance, Epidemiology, and End Results (SEER) data, this study was designed to assess the association between health insurance status and childhood cancer survival.

Breast cancer affects 1 in 8 women during their lives. Here's what you need to know about risk factors, symptoms, diagnosis, and treatment.
Significance of interleukin-6 (IL-6) in breast cancer (review)

Cytokines are factors that are known to have both tumor-promoting and inhibitory effects on breast cancer growth depending presumably on their relative concentrations and the presence of other modulating factors. Different cytokines play an important role in controlling the immune system. Interleukin-6 (IL-6) is a pleiotropic cytokine with obviously tumor-promoting and tumor-inhibitory effects. 

 

Cancer Reasearch, Immunotherapy
The Cancer Genes Needed for Immunotherapy Response

Using a large CRISPR-based screen, researchers find possible genetic culprits for patients not having success with immune checkpoint inhibitors. 

VIEW ALL ARTICLES

NEWSLETTER

Massive Bio is Your Advisor for Precision Cancer Care Options
Massive Bio Fights for You

Cancer patients, caregivers and oncologists - we would like to introduce ourselves as your next step toward fighting cancer. Massive Bio, Inc., headquartered in New York, is an innovative digital health company that brings the latest and greatest in cancer care to the point of need.

VIEW ALL ARTICLES
Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us by one of the options listed below:
Give Us a Call
+1 (917) 336-3319
Whatsapp
+ 57 322 277 9740
Toll Free
1 (844) 627-7246
Fax
1 (844) 742-8837
PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts:
1 (844) 627-7246
Top